A Randomized Phase 2 Study of Cediranib in Combination With Olaparib Versus Olaparib Alone in Men With Metastatic Castration Resistant Prostate Cancer

Trial Profile

A Randomized Phase 2 Study of Cediranib in Combination With Olaparib Versus Olaparib Alone in Men With Metastatic Castration Resistant Prostate Cancer

Recruiting
Phase of Trial: Phase II

Latest Information Update: 14 Sep 2017

At a glance

  • Drugs Cediranib (Primary) ; Olaparib (Primary)
  • Indications Adenocarcinoma; Prostate cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 10 Jun 2017 Biomarkers information updated
    • 04 Apr 2017 Status changed from suspended to recruiting.
    • 13 Jan 2017 Status changed from recruiting to suspended.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top